Janssen Ramps Up Ritalin and Opioid Production
Published Date: 2/18/2025
Notice
Summary
Janssen Pharmaceuticals wants to officially make big batches of three strong medicines: Methylphenidate, Hydromorphone, and Tapentadol. This move affects drug makers and users by ensuring these drugs are made safely and legally. People can share their thoughts or ask for a hearing by April 21, 2025, so don’t miss the deadline!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Janssen Seeks Bulk Manufacturer Registration
Janssen Pharmaceuticals applied on December 4, 2024 to be registered as a bulk manufacturer of three Schedule II controlled substances: Methylphenidate (code 1724), Hydromorphone (code 9150), and Tapentadol (code 9780). The company plans to bulk manufacture these substances as internal-use intermediates for sale to its customers, and the application is open for comments or hearing requests through April 21, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-02739, Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to make big batches of two powerful drugs, Ibogaine and MDMA, for research only. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 21, 2025. This move could boost scientific studies but doesn’t change drug sales or use rules.
Next: 2025-02777, Combined Notice of Filings
The Federal Energy Regulatory Commission got new filings about natural gas pipeline rates and refunds from several companies. These filings include updates to negotiated rates and compliance changes, with some taking effect as soon as February 11, 2025. If you want to speak up or get involved, you need to comment by late February, and these changes could affect pipeline costs and contracts.